Question 11 of 20 Fundamentals Concept
When is a placebo control ethical, and when is it not?
Short answer
A placebo control is usually ethical when no effective treatment exists, or when delaying treatment causes discomfort but no serious harm and participants are fully informed. It is generally inappropriate when an available treatment is known to prevent death or irreversible harm. An add-on design, where everyone gets standard care, often resolves the conflict.
Why
ICH E10 explains why placebo controls are valued: they show assay sensitivity, meaning the trial could detect a difference if one existed, and they measure the true effect of the drug rather than a difference from another drug. But E10 section 2.1.3 says that when an available treatment prevents serious harm, such as death or irreversible morbidity, a placebo control is generally inappropriate. It notes rare exceptions, for example when standard therapy is so toxic that many patients refuse it.
Where no serious harm is at stake, such as a short trial in mild seasonal allergy, a placebo arm can be ethical if the setting is noncoercive and patients know the alternatives. The Declaration of Helsinki takes a similar line. The common way through is an add-on design: all participants receive standard therapy, and the new drug or placebo is added on top.
Rescue medication and early escape rules also limit time on placebo. Ethics committees judge acceptability, and that judgment can differ between regions.
A strong answer covers
- Assay sensitivity as the scientific value of placebo
- Inappropriate when effective therapy prevents death or irreversible harm
- Acceptable for non-serious conditions with full information
- Add-on designs, rescue medication and early escape
- Ethics committee judgment and regional differences
Common mistakes
- Saying placebo controls are always unethical when any treatment exists.
- Forgetting that a placebo can be added on top of standard care.
- Assuming an active control trial is always more informative than a placebo trial.
The interviewer might ask next
Why is a noninferiority trial hard to interpret without evidence of assay sensitivity?